1. Home
  2. NGNE vs IBEX Comparison

NGNE vs IBEX Comparison

Compare NGNE & IBEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$20.61

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

Logo IBEX Limited

IBEX

IBEX Limited

HOLD

Current Price

$37.07

Market Cap

386.9M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
NGNE
IBEX
Founded
2003
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
327.8M
386.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
NGNE
IBEX
Price
$20.61
$37.07
Analyst Decision
Strong Buy
Hold
Analyst Count
6
3
Target Price
$38.50
$31.33
AVG Volume (30 Days)
188.3K
88.1K
Earning Date
11-13-2025
02-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
46.76
EPS
N/A
2.77
Revenue
N/A
$579,735,000.00
Revenue This Year
N/A
$12.15
Revenue Next Year
N/A
$5.68
P/E Ratio
N/A
$13.80
Revenue Growth
N/A
12.86
52 Week Low
$6.88
$20.18
52 Week High
$37.27
$42.99

Technical Indicators

Market Signals
Indicator
NGNE
IBEX
Relative Strength Index (RSI) 47.11 47.09
Support Level $19.28 $38.20
Resistance Level $22.99 $39.49
Average True Range (ATR) 1.44 1.00
MACD 0.32 -0.06
Stochastic Oscillator 40.15 2.03

Price Performance

Historical Comparison
NGNE
IBEX

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About IBEX IBEX Limited

IBEX Ltd delivers innovative business process outsourcing (BPO), smart digital marketing, online acquisition technology, and end-to-end customer engagement solutions to help companies acquire, engage, and retain valuable customers. It is an end-to-end provider of technology-enabled customer lifecycle experience (CLX) solutions to optimize customer acquisition, engagement, expansion, and experience for its clients. IBEX operates through the Business process outsourcing segment. Its services cover three areas: Digital and omni-channel Customer Experience (ibex Connect), Digital Marketing and E-Commerce (ibex Digital) and Digital CX surveys and analytics (ibex CX). It caters to a broad range of industries, such as telecommunications, cable, financial services, and healthcare.

Share on Social Networks: